J. AntonioGLopezMDFACC,FAHA,FACP,FNLA, FASH, FASPC

PubMed

• 2 citations
  Organ Donation and Transplantation among Non-US Citizens: Opportunities to Improve Global Equity in Heart Transplantation.
  Ersilia M Defilippis, Jaya Batra, Vanessa Blumer, Isaiah A Peoples, Christy N Taylor, Daniel Oren, Jose Lopez, Andrew J Sauer, Nasrien E Ibrahim> ;Journal of Cardiac Failure. 2023 Oct 1
• 138 citations
  Acute effect of cigarette smoking on the coronary circulation: constriction of epicardial and resistance vessels
  James E. Quillen, James D. Rossen, Helgi J. Oskarsson, Robert L. Minor, J.Antonio G. Lopez, Michael D. Winniford> ;Journal of the American College of Cardiology. 1993 Sep 1
• 3 citations
  Activation of leukocytes with complement C5a is associated with prostanoid-dependent constriction of large arteries in atherosclerotic monkeys in vivo.
  Andreas Mügge, Donald D. Heistad, Peter Densen, Donald J. Piegors, Mark L. Armstrong, Richard C. Padgett, J.Antonio G. Lopez> ;Atherosclerosis. 1992 Aug 1
• Effects of sympathetic nerves on collateral vessels in the limb of atherosclerotic primates.
  J.Antonio G. Lopez, Donald J. Piegors, Mark L. Armstrong, D. D. Heistad> ;Atherosclerosis. 1991 Oct 1
• 137 citations
  Comparison of coronary vasodilation with intravenous dipyridamole and adenosine
  James D. Rossen, James E. Quillen, J.Antonio G. Lopez, Robert G. Stenberg, Charlotte L. Talman, Michael D. Winniford> ;Journal of the American College of Cardiology. 1991 Aug 1
• 1 citations
  Atherosclerosis alters the response to activated platelets and leukocytes.
  Donald D. Heistad, J.Antonio G. Lopez, Mark L. Armstrong> ;Advances in Experimental Medicine and Biology. 1990 Jan 1
• Join now to see all

Journal Articles

• Quantification of LDL-Cholesterol corrected for molar concentration of Lp(a)  
  Rosenson, R.S., López, J.A.G., Monsalvo, M.L., Wu, Y., Wang, H., Marcovina, S.M., Cardiovasc Drugs Ther. 2022 https://doi.org/10.1007/s10557-022-07407-y., 2022
• Reduction of Lipoprotein(a) in Persons with Cardiovascular Disease  
  O'Donoghue, M.L., Rosenson, R.S., Gencer, B., López, J.A.G., Lepor, N.E., Baum, S. J., Stout, E., Gaudet, D., Knusel, B., Kuder, J.F., Ran, X., Murphy, S.A., Wang, H.,..., N Engl J Med. 2022; 387:1855-1864., 2022
• Long-Term Safety, Lipids, and Major Adverse Cardiovascular Events with Evolocumab in Patients with Established Atherosclerotic Cardiovascular Disease: Primary Results ...  
  O’Donoghue, ML., Giugliano, RP., Wiviott, SD., Atar, D., Keech, K., Kuder, J., Im, K., Murphy, S., Flores-Arredondo, JH., López, JAG., Elliott-Davey, M., Wang, B., Mon..., Circulation. 2022;146:1109-1119., 2022
• Long-term effects of evolocumab in patients with HIV and dyslipidemia: Results from the open-label extension period of the BEIJERINCK study  
  Boccara, F., Caramelli, B., Calmy, A., Kumar, P., López, J.A.G., Bray, S., Cyrille, M., and Rosenson, R.S., AIDS. 2022;36:675-682., 2022
• Lipoprotein(a) and the Risk for Coronary Heart Disease and Ischemic Stroke Events Among Black and White adults with Cardiovascular Disease  
  Colantonio, L.D., Bittner, V., Safford, M.M., Marcovina, S., Brown, T.D., Jackson, E.A., López, J.A.G., Monda, K.L., Plante, T.B., Kent, S., Muntner, P., and Rosenson,..., J Am Heart Assoc. 2022;11:e025397., 2022
• Study Design and Rationale for the OCEAN(a)-DOSE (Olpasiran trials of Cardiovascular Events And LipoproteiN(a) reduction-DOSE Finding Study) Trial  
  O'Donoghue, M.L, López, J.A.G., Knusel, B., Gencer, B., Wang, H., Wu, Y., Kassahun, H. and Sabatine M.S., Am. Heart J. 2022;251:61-69., 2022
• Diabetes Associated Residual Atherosclerotic Cardiovascular Risk in Statin-Treated Patients with Prior Atherosclerotic Cardiovascular Disease  
  Zhao, Y., Xiang, P., Coll, B., López, J.A.G., and Wong, N.D., J Diabetes Complications. 2021;35:107767., 2021
• Effects of Evolocumab on Low-Density Lipoprotein Cholesterol, Non–High Density Lipoprotein Cholesterol, Apolipoprotein B, and Lipoprotein(a) by Race and Ethnicity: A M...  
  Daviglus, M.L., Ferdinand, K.C., López, J.A.G., Wu, Y., Monsalvo, M.L., and Rodriguez, C.J., J Am Heart Assoc. 2021;10:e016839., 2021
• Effects of evolocumab in individuals with type 2 diabetes with and without atherogenic dyslipidemia: an analysis from BANTING and BERSON  
  Lorenzatti, A.J., Monsalvo, M.L, López, J.A.G., Wang, H., and Rosenson, R.S., Cardiovasc Diabetol. 2021; 20:94., 2021
• Evolocumab treatment in patients with HIV and hyperlipidemia/mixed dyslipidemia: BEIJERINCK study design and baseline characteristics  
  Boccara, F., Kumar, P., Caramelli, B., Calmy, A., López, J.A.G., Bray, S., Cyrille, M., and Rosenson, R.S., Am Heart J. 2020;220;203-212., 2020
• Long-Term Evolocumab in Patients with Familial Hypercholesterolemia  
  Santos, R.D., Stein, E.A., Hovingh, G.K., Blom, D.J., Soran, H., Watts, G.F., Lopez, J.A.G., Bray, S., Kurtz, C.E., Hamer, A.W., and Raal, F.J., J Am Coll Cardiol. 2020;75: 565-574., 2020
• Effect of Evolocumab on Non-High-Density Lipoprotein Cholesterol, Apolipoprotein B, and Lipoprotein(a): A Pooled Analysis of Phase 2 and Phase 3 Studies.  
  Toth, P.P., Jones, S.R., Monsalvo, M.L., Elliott-Davey, M., López, J.A.G., and Banach, M., J Am Heart Assoc. 2020;9: e014129., 2020
• Evolocumab Use in HIV-Infected Patients With Dyslipidemia: Primary Results of the Randomized, Double-blind BEIJERINCK Study.  
  Boccara, F., Kumar, P.N., Caramelli, B., Calmy, A., López, J.A.G., Bray, B., Cyrille, M., and Rosenson, R.S., J Am Coll Cardiol. 2020;75:2570-2584., 2020
• Evolocumab Effects on Lipoproteins, Measured by High-Performance Liquid Chromatography.  
  Masuda, D., Kiyosue, A., Hirayama, A., Shimauchi, J., Lopez, J.A.G., Miyawaki, K and Yamashita, S., J Atheroscler Thromb. 2020;27:1183-1207., 2020
• A Comparison of Ezetimibe and Evolocumab for Atherogenic Lipid Reduction in Four Patient Populations.  
  Koren, M.J., Jones, P.H., Robinson, J.G., Sullivan, D., Cho, L., MD, Hucko, T., Lopez, J.A.G., Fleishman, A.N., Somaratne, R., and Stroes, E., Cardiol Ther. 2020;9(2):447-465., 2020
• Five-Year Residual Atherosclerotic Cardiovascular Disease Risk Prediction Model for Statin Treated Patients with Known Cardiovascular Disease  
  Wong, N.D., Zhao, Y., Xiang, P., Coll, B., and López, J.A.G., Am J Cardiol. 2020;137:7−11., 2020
• Cardiovascular Events and Death after Myocardial Infarction or Ischemic Stroke in Older Medicare Population  
  Li, S., Wang, X., Quan, Y, Xiang P, Wade, SW., Guo, H., Lopez, J.A.G., Herzog, CA and Handelsman, Y., Clin. Cardiol. 2019;42:391–399, 2019
• Effects of Evolocumab on the ApoA1 Remnant Ratio: A Pooled Analysis of Phase 3 Studies  
  May, H., Muhlestein, J.B., Ma, Y., López, J.A.G., Crespo, B.C., and Nelson, J., Cardiol Ther. 2019;8:91-102., 2019
• Prevalence and Treatment of Familial Hypercholesterolemia Among Young Adults with Myocardial Infarction: the Partners YOUNG-MI Registry  
  Singh, A., Gupta, A., Collins, B.L., Qamar, A., Monda, K.L., Biery, D., Lopez, J.A.G., de Ferranti, S.D., Plutzky, J., Cannon, C.P., Januzzi, J.L., Marcelo F., Di Ca..., J Am Coll Cardiol. 2019;73: 2439–50., 2019
• The STatin Adverse Treatment Experience (STATE) Survey: Experience of Patients Reporting Side Effects of Statin Therapy  
  Cheeley, M.K., Jacobson, T., Jones, P., LaForge, R., Maki, K., Cheeley, M.K., López, J.A.G., Xiang, P., Bushnell, D., Martin, M., and Cohen, J.D., J Clin Lipidol. 2019;13:415-424., 2019
• PCSK9 loss-of-function variants and lipoprotein(a) phenotypes among black US adults.  
  Mefford, M.T., Marcovina, SM., Bittner, V., Cushman, M., Brown, TM., Farkouh, M.E., Tsimikas, S., Monda, K.L., López, J.A.G., Marcovina, SM., Muntner, P., and Rosenson..., J Lipid Res. 2019;60:1946–1952., 2019
• Residual atherosclerotic cardiovascular disease risk in statin-treated adults: The Multi-Ethnic Study of Atherosclerosis  
  Wong, N D., Zhao Y., Quek, R.G.W., Blumenthal, R.S., Budoff, M.J., Cushman, M., Garg, P., Sandfort, V. Tsai, M., and Lopez J.A.G, J Clin Lipidol. 2017;11:1223-1233, 2017
• Early Challenges for Patient Access to PCSK9 Inhibitors: Payor Rejections and Copay-Induced Abandonment.  
  Navar, A.M., Taylor B., Mulder, H., Fievitz, E., Monda, K., Fievitz, A., Maya, J., Lopez, J.A., and Peterson, E.D., JAMA Cardiol. 2017;2(11);1217-1225, 2017
• Nonbacterial Thrombotic Endocarditis (NBTE), A Review.  
  Lopez, J.A.G., Ross, R.S., Fishbein, M.C., and Siegel, R.J, Am. Heart J
• What Causes Spasm of Atherosclerotic Arteries? Is Regression of Plaques Beneficial?  
  Heistad, D.D., Armstrong, M.L., and Lopez, J.A.G, Trans. Amer. Clin. Climatol. Assoc
• Join now to see all

Books/Book Chapters

• Da La Mano A Tu Hermano. 
  Chapter: We Need Chicano Health Professionals 
  Page 1 - 2Lopez, J.A.: El ProblemaNational Chicano Health Organization, Harvard Medical School, Boston
• Pathobiology of the Human Atherosclerotic Plaque. 
  Chapter: Hemodynamic Consequences of Changes in the Artery Wall During Atherogenesis 
  Page 481 - 496Lopez, J.A., Harrison, D.G., Armstrong, M.L., and Heistad, D.DEditors: S. Glagov, W.P. Newmann III, and S.A. Schaffer.Springer-Verlag New York, New York
• Cardiovascular Clinics:Preventive Aspects of Coronary Heart Disease. 
  Chapter: Reversibility of Atherosclerosis 
  Page 113 - 126Armstrong, M.L., Heistad, D.D., Megan, M.D., Lopez, J.A.G., and Harrison, D.GEditors: E.D. Frohlich.F.A. Davis Company, Philadelphia
• Proceedings Volume of the International Symposium on “Serotonin:From Cell Biology to Pharmacology and Therapeutics. 
  Chapter: Responses to Serotonin in Atherosclerotic and Hypertensive Blood Vessels 
  Page 137 - 140Heistad, D.D., Lopez, J.A.G., and Mayhan, W.GEditors: R. Paoletti, P.M. Vanhoutte, N. Vbrunello, and F.M. Maggi.Kluwer Academic Publishers
• Endothelium-Derived Contracting Factors. 
  Chapter: Atherosclerosis Alters Vascular Responses to Activated Platelets and Leukocytes 
  Page 155 - 161Heistad, D.D., Lopez, J.A.G., and Armstrong, M.LEditors: G.M. Rubanyi and P.M. Vanhouette.S. Karger Publications, Basel, Switzerland
• Advances in Experimental Medicine and Biology:Tobacco Smoking and Atherosclerosis. 
  Chapter: Atherosclerosis Alters the Response to Activated Platelets and Leukocytes 
  Page 173 - 180Heistad, D.D., Lopez, J.A., and Armstrong, M.LEditors: J.N. Diana.Plenum Publishing Corporation, New York
• Drugs Affecting Lipid Metabolism (Int. Congr. Ser Exerpta Med). 
  Chapter: Old World Monkeys and Atherosclerosis Research 
  Page 485 - 488Armstrong, M.L., Heistad, D.D., Harrison, D.G., and Lopez, J.A.GEditors: A.M. Gotto and L.C. Smith.Elsevier Science Publishers
• Coronary Circulation in Physiological and Pathological States. 
  Chapter: Effects of Atherosclerosis and Regression of Lesions 
  Page 103 - 116Heistad, D.D., Lopez, J.A., Faraci, F.M., and Armstrong, M.LEditors: M. Nakamura and P.M. Vanhouette.Springer-Verlag Tokyo, Tokyo, Japan
• Progress and Promise for an Effective Quantitative Evaluation of Atherosclerosis in Animals and Man. 
  Chapter: Constriction and Dilatation in Atherosclerotic and Hypertensive Arteries 
  Page 251 - 260Heistad, D.D., Lopez, J.A.G., Faraci, F.M., and Armstrong, M.LEditors: R.W. Wissler, M.G. Bond, M. Mercuri and P. Tanganelli.Plenum Publishing Corporation, New York
• Transactions of the Association of American Physicians. 
  Chapter: Vascular Response to Activation of Leukocytes in Atherosclerotic Primates 
  Page 150 - 154Heistad, D.D., Lopez, J.A.G., Mugge, A., Densen, P., Padgett, R., and Armstrong, M.LWaverly Press, Baltimore
• Cardiovascular Therapeutics. 
  Chapter: Treatment of Hypertension in the Patient with Cardiovascular Disease 
  Page 503 - 514Haynes, W.G., Lopez, J.A.G., and Mark A.LEditors: T.W. Smith.W.B. Saunders Company, Philadelphia, PA
• Primary care Management of Heart Disease. 
  Chapter: Effects of Renal Disease on the Heart, Chapter 7, Section 44 
  Page 477 - 480Katholi, R.E., Lopez, J.A.G., and Bilinsky, R.TEditors: G.A. Taylor.Mosby, Inc, St. Louis, MO
• Join now to see all

Abstracts/Posters

• Detection of Early Necrosis in Low Flow Myocardial Ischemia Using Antimyosin.
  Timmis, A.D., Lopez, J.A., J.T., Khaw, B.A., Haber, E., and Powell, W.J, Circulation
• Neurogenic Vasoactive Properties of Ouabain.
  Lopez, J.A., Timmis, A.D., Garan, H., Homcy, C.S., and Powell, W.J, Circulation
• Role for 125I-Antimyosin (Fab) 2 in Early Detection of Myocardial Necrosis.
  Timmis, A.D., Lopez, J.A., Fallon, J.T., Khaw, B.A., Haber, E., and Powell, W.J, Br. Heart J
• Responsiveness of Ilial Collateral Vessels to Vasoconstrictor Stimuli in Normal and Atherosclerotic Primates.
  Lopez, J.A., Harrison, D.G., Armstrong, M.L., Piegors, D.J., and Heistad, D.D, Fed. Proc
• Responsiveness of Iliac Collateral Vessels to Vasoconstrictor Stimuli in Normal and Atherosclerotic Primates.
  Lopez, J.A., Harrison, D.G., Armstrong, M.L. Piegors, D.J., and Heistad, D.D, Clin. Res
• Vascular Responses to Platelet Products in Primates with Early and Advanced Atherosclerosis.
  Lopez, J.A., Armstrong, M.L., Piegors, D.J., and Heistad, D.D, Circulation
• Vascular Responses to Activated Platelets to Atherosclerotic Primates.
  Lopez, J.A., Brotherton, A.F.A., Armstrong, M.L., Piegors, D.J., and Heistad, D.D, FASEB J
• Role of Platelets and Leukocytes in Vasospasm.
  Lopez, J.A., Armstrong, M.L., and Heistad, D.D, Clin. Res
• Mechanisms of Vasospasm in Primates with Early Atherosclerosis.
  Lopez, J.A., Armstrong, M.L., and Heistad, D.D, Chest
• Vascular Responses to Endothelin in Atherosclerotic Primates.
  Lopez, J.A.G., Armstrong, M.L., Piegors, D.J., and Heistad, D.D, Circulation
• Effect of Intravascular Collagen in Atherosclerotic Primates.
  Lopez, J.A.G., Hoak, J.C., Armstrong, M.L., Piegors, D.J., and Heistad, D.D, J. Am. Coll. Cardiol
• Augmented Arterial Constriction to Serotonin in Atherosclerotic Primates: An Angiographic Study.
  Rossen, J.D., Piegors, D.J., and Lopez, J.A.G, FASEB J
• Response of Cerebral and Ocular Vessels to Activated Leukocytes in Atherosclerotic Primates.
  Lopez, J.A.G., Faraci, F.M., Breese, K.R., Armstrong, M.L., and Heistad, D.D, Clin. Res
• Vasoconstriction in Response to Activation of Leukocytes Persists After Regression of Atherosclerosis.
  Lopez, J.A.G., Mugge, A., Armstrong, M.L., Piegors, D.J., and Heistad, D.D, Clin. Res
• Activated Human Leukocytes Produce Endothelium-Independent Vasoconstriction in Normal and Atherosclerotic Primates in Vitro.
  Mugge, A., Lopez, J.A.G., Densen, P., Waack, B., and Heistad, D.D, Clin. Res
• Complement C5a Produces Vasoconstriction in Atherosclerotic But Not Normal Primates in Vivo.
  Lopez, J.A.G., Mugge, A., Densen, P., Piegors, D.J., Armstrong, M.L., and Heistad, D.D, Clin. Res
• Coronary Dilation with Intravenous Dipyridamole and Adenosine. A Comparative Study.
  Rossen, J.D., Stenberg, R.G., Lopez, J.A.G., Talman, C.L., and Winniford, M.D, Circulation
• Coronary Sinus Endothelin Levels Rise After Coronary Balloon Angioplasty.
  Kadel, K.A., Lopez, J.A.G., Rossen, J.D., Winniford, M.D., Talman, C.L., and Revtyak, G.R, Circulation
• Effect of Intravascular Complement C5a in Atherosclerotic Primates.
  Lopez, J.A.G., Mugge, A., Densen, P., Piegors, D.J., and Heistad, D.D, Circulation
• Cigarette Smoking Produces Constriction of Large Coronary Arteries in Humans.
  Quillen, J.E., Lopez, J.A.G., Rossen, J.D., Talman, C.L., and Winniford, M.D, J. Am. Coll. Cardiol
• Human Leukocytes Modulate Tone in Normal and Atherosclerotic Arteries in Vitro: Implications for Vasospasm.
  Mugge, A., Lopez, J.A.G., Densen, P., Waak, B.J., and Heistad, D.D, J. Am. Coll. Cardiol
• Vascular Responses to Activation of Leukocytes in Vivo After Regression of Atherosclerosis.
  Lopez, J.A.G., Mugge, A., Armstrong, M.L., Piegors, D.J., and Heistad, D.D, J. Am. Coll. Cardiol
• Vascular Response to Human Platelets: Intraluminal vs. Albuminal Activation.
  Kaul, S., Waak, B.J., Mugge, A., Padgett, R.C., Lopez, J.A.G., and Heistad, D.D, FASEB J
• Localization of the Increase in Coronary Vascular Resistance After Cigarette Smoking in Humans.
  Quillen, J.E., Rossen, J.D., Lopez, J.A.G., DeBoel, S.L., and Winniford, M.D, Circulation
• Vascular Effects of Leukocytes.
  Heistad, D.D., Lopez, J.A.G., Armstrong, M.L., and Mugge, A, J. Cell. Biochem
• Join now to see all

Lectures

• Emerging Cardiac Risk Factors and Treatment: A Focus on CRP and Fish Oil. 
  Medical Grand Rounds, Annenberg Center for Health Sciences. Eisenhower Medical Center. Rancho Mirage
• Optimizing LDL-Cholesterol Goal Achievement: An Evidenced Based Approach. 
  Multiple locations, 2007
• Current Concepts and Management of Congestive Heart Failure. 
  California Hispanic American Medical Association, Los Angeles, California
• Fenofibrate and the Management of Dyslipidemia. 
  Pasadena, California
• ACLS in Perspective. 
  Course in ACLS, Fallbrook Hospital District, Fallbrook, California
• Role of Advanced Lipid Testing in the Management of Dyslipidemia. 
  Desert Cardiology Center. Rancho Mirage, California
• Acute Myocardial Infarction. 
  Course in ACLS, Fallbrook Hospital District, Fallbrook, California
• Fenofibrate and the Management of Dyslipidemia. 
  El Centro, California
• Effect of Intravascular Collagen in Atherosclerotic Primates. 
  Endothelium and Vasomotion Session, 39th Annual Scientific Session, American College of Cardiology
• Hemodynamic Monitoring: Physiological Principles and Clinical Applications - Pulmonary Artery, Pulmonary Capillary Wedge, and Arterial Waveform Analysis. 
  Sharp Health Care Murrieta, Murrieta, California
• Current Concepts in the Treatment of Hypercholesterolemia. 
  Multiple locations
• New Strategies for Improved Survival in Patients with Diabetes or CHD. 
  Riverside, California
• Update in Management of Congestive Heart Failure. 
  Medical Grand Rounds, Fallbrook Hospital District, Fallbrook, California
• Evaluation of Chest Pain. 
  Medicine Residents Conference, Department of Internal Medicine, University of Iowa Hospitals&Clinics
• Lifestyle Modification in the Prevention of Cardiovascular Disease. 
  Congestive Heart Failure Support Group. Eisenhower Medical Center
• Response of Cerebral and Ocular Vessels to Activated Leukocytes in Atherosclerotic Primates. 
  Cardiovascular I: Coronary Atherosclerosis/Lipid Session, AAP/ASCI/AFCR National Meeting, Washington
• Advances in the Treatment of Acute Myocardial Infarction. 
  Progress in Internal Medicine: Clinical Reviews and Updates for the Primary Care Physician
• Effective Management of Hypercholesterolemia in the Hispanic Population. 
  Multiple locations
• Myocardial Infarction - Who and When to Refer. 
  Visiting Professor, Department of Family Practice, Iowa Lutheran Hospital, Des Moines, Iowa
• Does Baseline LDL-C Matter in Patients with Diabetes? 
  La Jolla, California
• Academic Medicine Versus Private Practice as a Career Choice. 
  Cardiovascular Fellows Meeting, Iowa City, Iowa
• Does Baseline LDL-Cholesterol Matter in Patients with Diabetes? 
  Multiple locations
• Secondary Prevention of Atherosclerosis. 
  The Healthy Heart Preventative Maintenance, 14th Annual Prairie Cardiovascular Consultants Symposium
• Managing Hypertension in the Changing Environment. 
  Palm Desert, California
• Slowing the Silent Progression: LDL-Cholesterol Lowering in Patients. 
  Multiple locations
• Join now to see all